Novel immunoassay for diagnosis of ongoing Clostridioides difficile infections using serum and medium enriched for newly synthesized antibodies (MENSA)

• Published in: Journal of immunological methods Vol. 492; p. 112932
• Main Authors: Haddad, Natalie S., Nozick, Sophia, Kim, Geena, Ohanian, Shant, Kraft, Colleen, Rebolledo, Paulina A., Wang, Yun, Wu, Hao, Bressler, Adam, Le, Sang Nguyet Thi, Kuruvilla, Merin, Cannon, L. Edward, Lee, F. Eun-Hyung, Daiss, John L.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.05.2021
• Subjects: Antibodies, Bacterial - analysis; Antibodies, Bacterial - immunology; Antibody; Antigens, Bacterial - immunology; Antigens, Bacterial - metabolism; Case-Control Studies; Cell Culture Techniques; Clostridioides difficile; Clostridioides difficile - immunology; Clostridioides difficile - isolation & purification; Clostridium Infections - blood; Clostridium Infections - diagnosis; Clostridium Infections - microbiology; Culture Media - metabolism; Diagnosis; Female; Humans; Leukocytes, Mononuclear - immunology; Leukocytes, Mononuclear - metabolism; Male; MENSA; Middle Aged; Recombinant Proteins - immunology; Recombinant Proteins - metabolism; Serologic Tests - methods; Toxins; Clostridioides difficile; MENSA; Toxins; Diagnosis; Antibody
• ISSN: 0022-1759; 1872-7905; 1872-7905
• DOI: 10.1016/j.jim.2020.112932

Clostridioides difficile infections (CDI) have been a challenging and increasingly serious concern in recent years. While early and accurate diagnosis is crucial, available assays have frustrating limitations. Develop a simple, blood-based immunoassay to accurately diagnose patients suffering from active CDI. Uninfected controls (N = 95) and CDI patients (N = 167) were recruited from Atlanta area hospitals. Blood samples were collected from patients within twelve days of a positive CDI test and processed to yield serum and PBMCs cultured to yield medium enriched for newly synthesized antibodies (MENSA). Multiplex immunoassays measured Ig responses to ten recombinant C. difficile antigens. Sixty-six percent of CDI patients produced measurable responses to C. difficile antigens in their serum or MENSA within twelve days of a positive CDI test. Fifty-two of the 167 CDI patients (31%) were detectable in both serum and MENSA, but 32/167 (19%) were detectable only in MENSA, and 27/167 (16%) were detectable only in serum. We describe the results of a multiplex immunoassay for the diagnosis of ongoing CDI in hospitalized patients. Our assay resolved patients into four categories: MENSA-positive only, serum-positive only, MENSA- and serum-positive, and MENSA- and serum-negative. The 30% of patients who were MENSA-positive only may be accounted for by nascent antibody secretion prior to seroconversion. Conversely, the serum-positive only subset may have been more advanced in their disease course. Immunocompromise and misdiagnosis may have contributed to the 34% of CDI patients who were not identified using MENSA or serum immunoassays. While there was considerable overlap between patients identified through MENSA and serum, each method detected a distinctive patient group. The combined use of both MENSA and serum to detect CDI patients resulted in the greatest identification of CDI patients. Together, longitudinal analysis of MENSA and serum will provide a more accurate evaluation of successful host humoral immune responses in CDI patients.